SARS-CoV-2
Molnupiravir: A welcome development but accessibility still a question

Dr. Satyajit Rath talks about key aspects of the new drug, Molnupiravir, and points out that a lot that needs attention to make sure the drug becomes accessible to the poorer nations

Origin of COVID-19 Close relative of SARS-CoV-2 virus found in bats in Laos

Three bat species had viruses that are more than 95% identical with the one that causes COVID-19, a study found. This further boosts the argument that the SARS-CoV-2 virus had a natural origin

COVID-19: Autoantibodies can cause severe disease and deaths

Various studies have revealed that autoantibodies have been a key driver of severe illness and deaths amongst people critically infected with COVID-19. Findings also show that autoantibodies’ concentration in human bodies increases with age

What do we know about the Lambda variant?

The Lambda variant, which was first identified in Peru, was declared as a variant of interest by the World Health Organization in June. It has reportedly spread to at least 31 countries

How to know if a virus variant can escape vaccine protection

Amid new variants of the SARS-CoV-2 emerging across the world, experts explain how to ascertain whether a virus strain can escape the protection provided by a vaccine

Cuba: crisis, blockade and changes in 2021

Luis De Jesus writes about how Cuba plans to take on 2021, looking closely at the new ambitious economic development strategy “the Ordering Task”

One year of COVID-19: The known and the unknown

The global response to the COVID-19 pandemic in terms of developing a vaccine has been unprecedented. However, there is still a lot to be understood about the disease and the virus which causes

How dangerous is the new COVID-19 strain?

Immunologist Dr. Satyajit Rath talks about reports of a strain of COVID-19 from the UK, the transmission rate and its implications on public health policy

COVID-19 reinfection: Virus could hide itself in human chromosome, finds new study

The novel coronavirus can integrate its genetic material or RNA into human chromosome and reproduce itself, the study suggests

COVID-19 vaccine: Rich countries might gain, poor ones might suffer

As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard

COVID-19: What we know about asymptomatic patients so far

Are asymptomatic people the real drivers of COVID-19 progression? Researchers are divided as more studies arrive that further complicate the question

COVID-19: Study suggests immunity against SARS-CoV-2 could last for six months

The study analyzed the immune memory against the virus in 185 patients who had recovered from COVID-19. These included patients who were asymptomatic and those who exhibited severe clinical symptoms

    × To Subscribe